16.54
price down icon1.02%   -0.17
after-market Handel nachbörslich: 16.16 -0.38 -2.30%
loading
Schlusskurs vom Vortag:
$16.71
Offen:
$16.67
24-Stunden-Volumen:
529.93K
Relative Volume:
1.53
Marktkapitalisierung:
$488.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$11.77M
KGV:
28.59
EPS:
0.5785
Netto-Cashflow:
$-19.23M
1W Leistung:
-0.60%
1M Leistung:
+6.78%
6M Leistung:
-20.02%
1J Leistung:
+25.02%
1-Tages-Spanne:
Value
$16.33
$17.03
1-Wochen-Bereich:
Value
$16.33
$17.70
52-Wochen-Spanne:
Value
$11.56
$29.79

Tourmaline Bio Inc Stock (TRML) Company Profile

Name
Firmenname
Tourmaline Bio Inc
Name
Telefon
646-481-9832
Name
Adresse
27 WEST 24TH STREET, NEW YORK
Name
Mitarbeiter
74
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
TRML's Discussions on Twitter

Vergleichen Sie TRML mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TRML
Tourmaline Bio Inc
16.54 488.08M 0 11.77M -19.23M 0.5785
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-23 Eingeleitet Chardan Capital Markets Buy
2025-03-06 Eingeleitet Wedbush Outperform
2024-12-06 Eingeleitet BMO Capital Markets Outperform
2024-11-11 Bestätigt H.C. Wainwright Buy
2023-12-15 Eingeleitet Jefferies Buy
2023-12-04 Fortgesetzt H.C. Wainwright Buy
2023-11-17 Eingeleitet Truist Buy
2023-10-31 Eingeleitet Guggenheim Buy
2023-10-25 Eingeleitet Piper Sandler Overweight
2022-10-20 Eingeleitet H.C. Wainwright Buy
2022-07-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
Alle ansehen

Tourmaline Bio Inc Aktie (TRML) Neueste Nachrichten

pulisher
Jun 13, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by California State Teachers Retirement System - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Tourmaline Bio Releases Updated Corporate Presentation - TipRanks

Jun 09, 2025
pulisher
Jun 06, 2025

Tourmaline Bio Elects Directors and Ratifies Auditor - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Nuveen Asset Management LLC Has $1.55 Million Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Reduces Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Jane Street Group LLC Cuts Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $291,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 31, 2025
pulisher
May 30, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 30, 2025
pulisher
May 29, 2025

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN

May 29, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey

May 28, 2025
pulisher
May 27, 2025

H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

H.C. Wainwright maintains $50 target on Tourmaline Bio stock - Investing.com

May 27, 2025
pulisher
May 27, 2025

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 27, 2025
pulisher
May 26, 2025

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World

May 26, 2025
pulisher
May 25, 2025

Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com

May 25, 2025
pulisher
May 23, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World

May 23, 2025
pulisher
May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com

May 21, 2025
pulisher
May 21, 2025

Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter

May 21, 2025
pulisher
May 21, 2025

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive

May 20, 2025
pulisher
May 20, 2025

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares edge lower despite phase 2 trial results By Investing.com - Investing.com South Africa

May 20, 2025
pulisher
May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan

May 19, 2025

Finanzdaten der Tourmaline Bio Inc-Aktie (TRML)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Tourmaline Bio Inc-Aktie (TRML) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Kulkarni Sandeep Chidambar
CEO
Aug 16 '24
Buy
13.79
5,221
71,998
5,221
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):